Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Clin Med ; 13(8)2024 Apr 18.
Artigo em Inglês | MEDLINE | ID: mdl-38673626

RESUMO

Background: There is evidence suggesting the existence of sex differences in the effectiveness of specific drug classes for rheumatoid arthritis (RA). Our study stands as the first to elucidate sex-related differences in the effectiveness of Janus kinase (JAK) inhibitors. Methods: The study involved 150 RA patients treated with tofacitinib, baricitinib, upadacitinib, or filgotinib between September 2017 and October 2023. Sex differences in achieving remission and low disease activity (LDA) were identified through logistic regression analyses. Sex disparities in treatment effectiveness survival were evaluated through the Kaplan-Meier estimate, employing the log-rank test for comparison. The Cox model was applied to analyze the variable sex as a potential factor that could influence the maintenance of the JAK inhibitor treatment effectiveness. Results: Concerning the achievement of remission and LDA, no differences were observed between sexes in terms of the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP), the Clinical Disease Activity Index (CDAI), and the Simplified Disease Activity Index (SDAI). With respect to the DAS28-erythrocyte sedimentation rate (ESR), female patients, compared to males, possessed 70% lower odds of achieving remission (p = 0.018) and 66% lower odds of achieving LDA (p = 0.023). No differences were observed in treatment effectiveness survival between sexes (p = 0.703). Sex was not found to influence the survival of JAK inhibitor treatment effectiveness (p = 0.704). Conclusions: Being a female or male patient does not entail differences in the effectiveness of the JAK inhibitor treatment. Our findings encourage the consideration of a global pool of composite indices (DAS28-ESR/CRP, CDAI, SDAI) to measure RA disease activity, thus individualizing the target value as advocated by the treat-to-target strategy.

2.
Medicina (Kaunas) ; 60(3)2024 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-38541086

RESUMO

Background and Objectives: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving ß-cell function. However, the clinical evidence currently available is limited. We aimed to assess the potential impact of tofacitinib and baricitinib on type 2 diabetes mellitus (T2DM) patients with rheumatoid arthritis. Materials and Methods: The candidates for this observational, retrospective, single-center study were selected from a cohort of 120 rheumatoid arthritis patients treated with tofacitinib or baricitinib between September 2017 and September 2023. The eligibility criteria included patients with T2DM who were receiving oral antidiabetic drugs (OADs). The primary outcome was the glycosylated hemoglobin (HbA1c) value after 6 months of a JAK inhibitor treatment. Secondary outcomes included body mass index (BMI) and rheumatoid arthritis disease activity. Differences were evaluated using Fisher's exact test, as well as the Mann-Whitney test or the Wilcoxon test. Results: Thirteen patients were included; 46.2% (6/13) underwent treatment with tofacitinib, while 53.8% (7/13) were treated with baricitinib. At 6 months, baricitinib treatment resulted in a reduction in HbA1c (p = 0.035), with 57.1% (4/7) of patients achieving values <7%, and 28.6% (2/7) of patients requiring a reduction in OAD dosage. Concerning BMI, an increase (p = 0.022) was observed at 6 months following baricitinib administration. All the patients treated with either tofacitinib or baricitinib achieved remission or low disease activity, without requiring statistically significant changes in concomitant rheumatoid arthritis treatment. Conclusions: In T2DM patients with rheumatoid arthritis, baricitinib can improve insulin sensitivity and glucose uptake, enabling the optimization of T2DM management.


Assuntos
Artrite Reumatoide , Azetidinas , Diabetes Mellitus Tipo 2 , Piperidinas , Purinas , Pirazóis , Pirimidinas , Sulfonamidas , Humanos , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hemoglobinas Glicadas , Estudos Retrospectivos , Resultado do Tratamento
3.
Sci Rep ; 14(1): 172, 2024 01 02.
Artigo em Inglês | MEDLINE | ID: mdl-38168532

RESUMO

In real-world scenarios, Janus Kinase (JAK) inhibitors are often offered to "difficult-to-treat" rheumatoid arthritis patients, quite different from those included in randomized controlled trials. Our study aimed to evaluate the influence of patient-related factors on the effectiveness and safety of JAK inhibitors in real-world clinical practice. This observational retrospective study involved rheumatoid arthritis patients who received treatment with either tofacitinib, baricitinib, upadacitinib, or filgotinib. At 12 months of treatment, reasons for and rates of JAK inhibitor treatment discontinuation were examined. Treatment retentions were analyzed through Cox proportional hazard regression models and Kaplan-Meier estimates. Patient-related factors that could influence treatment retention were evaluated for the discontinuation reasons of lack of effectiveness and adverse events. At 12 months of treatment, discontinuation rates for 189 JAK inhibitor treatments were: lack of effectiveness (24.3%), adverse events (20.6%), and other reasons (3.7%). The remaining 51.4% represents the treatment continuation rate. No patient-related factors evaluated had an influence on treatment discontinuation due to lack of effectiveness. Ae significantly increased the risk of treatment discontinuation due to adverse events (p = 0.030). In terms of age, at 12 month of treatment, discontinuation rates due to adverse events were: < 65 years, 14.4% vs. 65 years or older, 26.3% (p = 0.019). Rheumatoid arthritis patients aged 65 years or older showed an increased risk of JAK inhibitor treatment discontinuation due to adverse events. Factors not related to treatment discontinuation were: sex, rheumatoid arthritis disease duration, rheumatoid arthritis disease activity, seropositivity for rheumatoid factor, seropositivity for anti-cyclic citrullinated peptides, number of prior biologic treatments, number of prior JAK inhibitor treatments, concomitant use of glucocorticoids, and concomitant use of conventional synthetic disease-modifying antirheumatic drugs.


Assuntos
Antirreumáticos , Artrite Reumatoide , Inibidores de Janus Quinases , Humanos , Pré-Escolar , Inibidores de Janus Quinases/efeitos adversos , Estudos Retrospectivos , Resultado do Tratamento , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/induzido quimicamente , Antirreumáticos/efeitos adversos
4.
J Clin Med ; 12(3)2023 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-36769579

RESUMO

The aim was to identify patient- and disease-related characteristics predicting moderate-to-high disease activity in recent-onset psoriatic arthritis (PsA). We performed a multicenter observational prospective study (2-year follow-up, regular annual visits) in patients aged ≥18 years who fulfilled the CASPAR criteria and had less than 2 years since the onset of symptoms. The moderate-to-high activity of PsA was defined as DAPSA > 14. We trained a logistic regression model and random forest-type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis. The sample comprised 158 patients. At the first follow-up visit, 20.8% of the patients who attended the clinic had a moderate-to-severe disease. This percentage rose to 21.2% on the second visit. The variables predicting moderate-high activity were the PsAID score, tender joint count, level of physical activity, and sex. The mean values of the measures of validity of the machine learning algorithms were all high, especially sensitivity (98%; 95% CI: 86.89-100.00). PsAID was the most important variable in the prediction algorithms, reinforcing the convenience of its inclusion in daily clinical practice. Strategies that focus on the needs of women with PsA should be considered.

5.
Clin Exp Rheumatol ; 41(1): 137-144, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-35699067

RESUMO

OBJECTIVES: To evaluate the effect of potential confounders on the association between sex and disease impact in recent-onset psoriatic arthritis. METHODS: We performed a multicentre observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged ≥18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. The dataset was generated using data for each patient at the 3 visits (baseline, first year, and second year of follow-up) matched with the PsAID values at each of the 3 visits. Once variables associated with both PsAID ≥4 and sex were selected, those that led to a difference of >10% between the adjusted and crude estimations were identified as potential confounders in the association between sex and PsAID. Lastly, the final multivariate logistic regression model estimating the association between sex and PsAID was defined. RESULTS: The dataset contained 418 observations (158 at baseline, 135 at the first follow-up visit, and 125 at the second visit). The confounders identified in the multivariate model were HAQ, global pain, level of physical activity, and joint pattern at diagnosis. After adjustment for these variables, no statistically significant association was observed between female sex and PsAID ≥4. CONCLUSIONS: The association between female sex and greater disease impact could be explained by the influence of other variables, specifically higher HAQ score, greater intensity of pain, differences in the level of physical activity and in the joint pattern at diagnosis (lower frequency of the spondylitis pattern in women).


Assuntos
Artrite Psoriásica , Adolescente , Adulto , Feminino , Humanos , Artrite Psoriásica/diagnóstico , Dor , Estudos Prospectivos , Índice de Gravidade de Doença
6.
J Obstet Gynaecol Res ; 37(2): 138-45, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21159038

RESUMO

AIM: To compare socioeconomic status and pregnancy outcomes in relation to different pre-pregnancy body mass index (BMI) levels, and to determine whether gestational weight gain is related to socioeconomic status and pregnancy outcomes. METHODS: This was a retrospective cohort study of 3554 singleton pregnancies. Gravidas were grouped into three BMI categories and in three gestational weight gain categories. We performed multivariate analyses for the associations between pre-pregnancy BMI, gestational weight gain, socioeconomic status, and pregnancy outcomes. RESULTS: Overweight gravidas had shorter gestational weeks, decreased birthweight, and increased frequency of preterm birth (P < 0.05). There were higher percentages of low levels of education and low economic status in the overweight gravidas and their husbands (P < 0.05). There were also higher percentages of low levels of education in gravidas with a low weight gain during pregnancy and their husbands, and gravidas with low weight gain had increased frequency of preterm deliveries (P < 0.05). Overweight gravidas had a higher risk for preeclampsia (adjusted OR, 2.4) and gestational diabetes (adjusted OR, 2.0). Overweight gravidas and women with excessive weight gain during pregnancy had higher risks for cesarean section (unadjusted OR, 1.6), macrosomia (unadjusted OR, 2.7) and large for gestational age (LGA) (adjusted OR, 2.4). A higher risk for small gestational age (SGA) fetuses existed in normoweight gravidas and gravidas with low weight gain during pregnancy (unadjusted OR, 2.8). CONCLUSION: Overweight gravidas were associated with low education status, low economic status, and adverse pregnancy, whereas low weight gain during pregnancy was associated with low education status of the gravida and her husband, preterm delivery, and SGA.


Assuntos
Índice de Massa Corporal , Resultado da Gravidez/epidemiologia , Gravidez/estatística & dados numéricos , Classe Social , Adulto , Pesos e Medidas Corporais , Estudos de Coortes , Feminino , Hospitais Universitários , Humanos , Análise Multivariada , Obesidade/complicações , Obesidade/epidemiologia , Razão de Chances , Gravidez/fisiologia , Complicações na Gravidez/epidemiologia , República da Coreia/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Fatores Socioeconômicos , Inquéritos e Questionários , Aumento de Peso , Serviços de Saúde da Mulher
7.
Obesity (Silver Spring) ; 18(11): 2105-10, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20339362

RESUMO

Visceral adipose tissue-derived serpin (vaspin) has been regarded as a novel adipokine with potential insulin sensitizing properties. We investigated the changes of serum vaspin concentration in response to weight reduction, and the associations between changes in serum vaspin concentrations and changes of anthropometric and metabolic variables in obese subjects after weight reduction. We performed a longitudinal clinical intervention study on 63 obese persons enrolled in a 12-week weight reduction program that included lifestyle modification and adjuvant treatment with the antiobesity agent orlistat. Anthropometric variables, lipid profiles, fasting glucose, fasting insulin, and serum vaspin concentrations were measured. Statistical analyses were performed according to the homeostasis model assessment of insulin resistance (HOMA(IR)). Serum vaspin concentrations decreased significantly in responders (≥2% reduction in baseline weight), but not in nonresponders (<2% reduction in baseline weight). Changes in serum vaspin concentrations were significantly correlated with body weight, BMI, waist circumference, and hip circumference in the higher, but not in the lower, HOMA(IR) group. In multivariate linear regression analysis, change in serum vaspin concentrations in the higher, but not in the lower, HOMA(IR) group was positively correlated with change in BMI and negatively correlated with initial HOMA(IR) level. The associations between changes in serum vaspin concentrations and changes in anthropometric and metabolic parameters differed according to insulin resistance status in obese subjects. These relationships were more prominent in the higher HOMA(IR) group. Insulin resistance may influence the correlations between changes in serum vaspin concentration and related metabolic variables.


Assuntos
Índice de Massa Corporal , Resistência à Insulina/fisiologia , Obesidade/sangue , Serpinas/sangue , Redução de Peso/fisiologia , Adulto , Fármacos Antiobesidade/uso terapêutico , Peso Corporal , Feminino , Quadril/anatomia & histologia , Humanos , Lactonas/uso terapêutico , Estilo de Vida , Estudos Longitudinais , Masculino , Obesidade/tratamento farmacológico , Orlistate , Resultado do Tratamento , Circunferência da Cintura
8.
Obesity (Silver Spring) ; 16(6): 1434-9, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18388894

RESUMO

Obesity and insulin resistance are associated with the risk of colon cancer. Adenomatous colonic polyps are precancerous lesions of colon cancer. We investigated whether BMI and the metabolic syndrome are associated with the presence of adenomatous colonic polyps in Korean men. Anthropometric measurements, metabolic risk factors, and colonoscopic pathologic findings were assessed in 1,898 men who underwent routine colonoscopy at the Health Promotion Center of Asan Medical Center in 2005. The modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria were used for the definition of the metabolic syndrome. Multiple logistic regression analysis was used to evaluate the association between BMI and the metabolic syndrome and adenomatous polyps. Compared with men in the 1st quintile of the BMI, the adjusted odds ratio (OR) and 95% confidence interval (CI) for adenomatous polyps in men in the 2nd, 3rd, 4th, and 5th quintiles of the BMI were 1.55 (1.10-2.19), 1.57 (1.10-2.24), 1.94 (1.34-2.81), and 1.99 (1.31-3.01), respectively (P for trend <0.0001). Men with triglycerides (TGs) > or = 150 mg/dl were significantly more likely to have adenomatous polyps than were men with TG <150 mg/dl (OR 1.29; 95% CI 1.03-1.62). As a function of the number of metabolic risk factors, the ORs for adenomatous polyps were 1.41 (1.03-1.93), 1.52 (1.08-2.12), 1.46 (1.01-2.12), and 1.77 (1.08-2.90) for 1, 2, 3, and > or = 4 risk factors, respectively (P for trend <0.05). Adenomatous colonic polyps were significantly associated with increased BMI levels. Subjects with even one component of the metabolic syndrome had a significantly higher risk for developing adenomatous polyps compared to those subjects without any component in Korean men.


Assuntos
Pólipos Adenomatosos/epidemiologia , Índice de Massa Corporal , Pólipos do Colo/epidemiologia , Síndrome Metabólica/fisiopatologia , Pólipos Adenomatosos/etnologia , Pólipos do Colo/etnologia , Inquéritos Epidemiológicos , Humanos , Incidência , Coreia (Geográfico)/epidemiologia , Modelos Logísticos , Masculino , Síndrome Metabólica/etnologia , Pessoa de Meia-Idade , Fatores de Risco , Triglicerídeos/sangue
9.
Menopause ; 10(3): 222-7, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12792294

RESUMO

OBJECTIVE: Visceral adipose tissue (VAT) is increased in the postmenopausal state, which may contribute to an increase in cardiovascular diseases. This study was undertaken to investigate whether there is a difference in the change of VAT during a weight reduction program between premenopausal and postmenopausal obese women. DESIGN: This study was a longitudinal clinical intervention of a weight reduction program, including lifestyle modification and adjuvant pharmacotherapy, for 12 weeks in 21 premenopausal and 19 postmenopausal obese women. Weight, height, body fat percentage, and waist and hip circumferences were measured. Visceral, subcutaneous, and total adipose tissue of the abdomen were determined by CT scan at the level of L4-L5 before and after weight reduction. RESULTS: The percent changes in VAT and the visceral-to-subcutaneous adipose tissue ratio, as well as waist circumference and waist-to-hip ratio, in the postmenopausal women were significantly less than those in the premenopausal women, whereas the percent changes in hip circumference, fat mass, total adipose tissue, and subcutaneous adipose tissue were similar in the two groups. The association between percent changes of VAT and the percent change of waist circumference is stronger in postmenopausal than in premenopausal women. CONCLUSIONS: The postmenopausal women lost less VAT compared with the premenopausal women during the weight reduction program. This may make it more difficult for postmenopausal women to overcome the increased risk of cardiovascular diseases compared with premenopausal women.


Assuntos
Tecido Adiposo/fisiologia , Composição Corporal/fisiologia , Obesidade/terapia , Pós-Menopausa/fisiologia , Redução de Peso/fisiologia , Abdome , Tecido Adiposo/patologia , Adulto , Povo Asiático , Índice de Massa Corporal , Dieta Redutora , Ingestão de Energia , Feminino , Humanos , Coreia (Geográfico) , Estilo de Vida , Estudos Longitudinais , Pessoa de Meia-Idade , Obesidade/fisiopatologia , Educação Física e Treinamento , Pré-Menopausa/fisiologia , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...